Iron Sucrose: A Double-Edged Sword in High Phosphate Media-Induced Vascular Calcification

Overview

Journal Calcif Tissue Int

Specialty Pathology

Date 2021 Jan 13

PMID 33439323

Citations 2

Authors

Ping Wang

Chengkun Guo

Hui Pan

Wangshan Chen

Dan Peng

Affiliations

Soon will be listed here.

Abstract

The high incidence of vascular calcification (VC) in patients with chronic kidney disease (CKD) has become an important clinical subject. Hyperphosphatemia is a primary cause of CKD-related VC. Intravenous iron sucrose (IS) is commonly used to treat anemia in CKD patients, and is effective and well tolerated worldwide. However, the interaction between iron and VC remains controversial, and the underlying mechanisms are yet to be clarified. In the present study, ex vivo normal rat aortic rings were cultured with various concentrations of phosphate and IS, and the levels of calcium and iron depositions, oxidative injury, as well as phenotypic marker genes were detected. To the best of our knowledge, the present study is the first to report that IS is a double-edged sword in high phosphate media-induced VC which not only alleviates VC in a dose-dependent manner but also leads to iron overload in vasculature when in high concentration. IS is a promising agent for VC prevention in patients with hyperphosphatemia and iron deficiency. Meanwhile, the appropriate blood concentration of IS in patients with hyperphosphatemia needs to be explored clinically.

Citing Articles

Hypoxia-Inducible Factor-1 Regulates High Phosphate-Induced Vascular Calcification via Type III Sodium-Dependent Phosphate Cotransporter 1.

Guo C, Quan Z, Ke J, Zang H, Teng Q, Li X Cardiol Res Pract. 2024; 2024:6346115.

PMID: 38566807 PMC: 10987242. DOI: 10.1155/2024/6346115.

Iron overload impairs renal function and is associated with vascular calcification in rat aorta.

Song Y, Yang N, Si H, Liu T, Wang H, Geng H Biometals. 2022; 35(6):1325-1339.

PMID: 36178540 PMC: 9674728. DOI: 10.1007/s10534-022-00449-7.

References

Ohya M, Otani H, Kimura K, Saika Y, Fujii R, Yukawa S . Vascular calcification estimated by aortic calcification area index is a significant predictive parameter of cardiovascular mortality in hemodialysis patients. Clin Exp Nephrol. 2011; 15(6):877-83. DOI: 10.1007/s10157-011-0517-y. View

Mizobuchi M, Towler D, Slatopolsky E . Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009; 20(7):1453-64. DOI: 10.1681/ASN.2008070692. View

Giachelli C . Vascular calcification mechanisms. J Am Soc Nephrol. 2004; 15(12):2959-64. DOI: 10.1097/01.ASN.0000145894.57533.C4. View

Shanahan C, Crouthamel M, Kapustin A, Giachelli C . Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011; 109(6):697-711. PMC: 3249146. DOI: 10.1161/CIRCRESAHA.110.234914. View

Gross P, Six I, Kamel S, Massy Z . Vascular toxicity of phosphate in chronic kidney disease: beyond vascular calcification . Circ J. 2014; 78(10):2339-46. DOI: 10.1253/circj.cj-14-0735. View

Shroff R, Long D, Shanahan C . Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol. 2012; 24(2):179-89. DOI: 10.1681/ASN.2011121191. View

Babitt J, Lin H . Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012; 23(10):1631-4. PMC: 3458456. DOI: 10.1681/ASN.2011111078. View

Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A . Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis. Am J Kidney Dis. 2016; 68(5):677-690. DOI: 10.1053/j.ajkd.2016.04.018. View

Macdougall I, Geisser P . Use of intravenous iron supplementation in chronic kidney disease: an update. Iran J Kidney Dis. 2013; 7(1):9-22. View

10.

Charytan D, Pai A, Chan C, Coyne D, Hung A, Kovesdy C . Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol. 2014; 26(6):1238-47. PMC: 4446883. DOI: 10.1681/ASN.2014090922. View

11.

Macdougall I, Bircher A, Eckardt K, Obrador G, Pollock C, Stenvinkel P . Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2016; 89(1):28-39. DOI: 10.1016/j.kint.2015.10.002. View

12.

Del Vecchio L, Longhi S, Locatelli F . Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J. 2016; 9(2):260-7. PMC: 4792617. DOI: 10.1093/ckj/sfv142. View

13.

Drakesmith H, Prentice A . Hepcidin and the iron-infection axis. Science. 2012; 338(6108):768-72. DOI: 10.1126/science.1224577. View

14.

Ganguli A, Kohli H, Khullar M, Gupta K, Jha V, Sakhuja V . Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease. Ren Fail. 2009; 31(2):106-10. DOI: 10.1080/08860220802599106. View

15.

Neiser S, Rentsch D, Dippon U, Kappler A, Weidler P, Gottlicher J . Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. Biometals. 2015; 28(4):615-35. DOI: 10.1007/s10534-015-9845-9. View

16.

Macdougall I, Strauss W, Dahl N, Bernard K, Li Z . Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial . Clin Nephrol. 2019; 91(4):237-245. PMC: 6434426. DOI: 10.5414/CN109512. View

17.

Macdougall I, White C, Anker S, Bhandari S, Farrington K, Kalra P . Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. Am J Nephrol. 2018; 48(4):260-268. PMC: 6262676. DOI: 10.1159/000493551. View

18.

Macdougall I, White C, Anker S, Bhandari S, Farrington K, Kalra P . Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. N Engl J Med. 2018; 380(5):447-458. DOI: 10.1056/NEJMoa1810742. View

19.

Seto T, Hamada C, Tomino Y . Suppressive effects of iron overloading on vascular calcification in uremic rats. J Nephrol. 2014; 27(2):135-42. PMC: 3958811. DOI: 10.1007/s40620-014-0046-3. View

20.

Ciceri P, Elli F, Braidotti P, Falleni M, Tosi D, Bulfamante G . Iron citrate reduces high phosphate-induced vascular calcification by inhibiting apoptosis. Atherosclerosis. 2016; 254:93-101. DOI: 10.1016/j.atherosclerosis.2016.09.071. View